Saudi regulator bars United Cooperative Assurance from issuing or renewing all policies

Key Facts

Saudi Arabia's Insurance Authority barred United Cooperative Assurance from issuing or renewing policies across all its products effective 22 September 2026, widening restrictions that had already covered parts of the business. The order includes policies sold to individuals and the extended-warranty product, the regulator said. Existing policies and the claims arising from them remain the company's responsibility despite the ban on new issuance and renewals. The decision comes while trading in the insurer's shares, ticker 8190, has been suspended since 13 September 2026 following a petition to open liquidation proceedings. There is therefore no current exchange-traded share-price reaction to observe, although the expanded ban matters to the insurer's ability to rebuild sales.

The authority defined the restriction as a ban on new issuance and renewals; it did not announce that existing cover had been cancelled. That distinction matters to customers because a sales ban does not extinguish claims arising under a policy still in force. The regulator said the insurer remains responsible for those policies, resulting claims and measures needed to protect beneficiaries. It framed the action as protecting policyholder rights and sector stability, as well as improving insurers' ability to meet their obligations. The authority cited violations of supervisory and regulatory instructions but did not itemize them in its statement, leaving the likely duration and precise conditions for lifting the ban unclear.

The first economic effect is on the flow of future business, rather than the immediate disappearance of every accounting revenue line. An insurer unable to issue or renew policies loses a source of new premiums, and its portfolio can shrink as contracts expire if the restriction persists. Revenue may still be recognized as cover is provided under policies written earlier. Claims, expenses and obligations tied to those policies also remain, so a sales ban does not make every cash flow disappear at once. Assessing the net effect on cash, earnings and solvency requires later disclosures about the remaining portfolio and its liabilities. Treating the order as an instant cancellation of every policy or all revenue would overstate what the regulator announced.

The latest decision follows a sequence of increasingly broad regulatory restrictions. On 27 October 2025, the authority halted issuance and renewal of the company's mandatory insurance products, including health, motor and domestic-worker contract cover. On 19 February 2026, it extended the restriction to every motor product, including comprehensive cover. The 22 September 2026 order covers the full insurance product range. That chronology shows that the scope available for new sales had narrowed before the latest step, so the effect of earlier restrictions must be distinguished from the newest expansion. It does not, by itself, quantify how much each measure contributed to weaker business or identify any particular financial figure as the cause of the latest order.

The insurer's first-half 2026 results show the contraction preceding the all-product order. Insurance revenue was 188.973 million riyals, against 430.431 million riyals in the comparable first half, a decline of about 56%. Second-quarter revenue was 88.288 million riyals, down from 211.278 million riyals a year earlier, or about 58%. The company attributed the revenue decreases chiefly to a decline in business. Those figures provide a useful baseline for comparison with later results because the reporting periods ended before the full-product restriction. They cannot be presented as losses already caused by the September order, though they show the weak operating position from which the insurer entered the broader ban.

Gross written premiums, a measure closer to the policies entering the portfolio, had also contracted before the latest expansion. The company reported 201.308 million riyals of gross written premiums for the first half, compared with 494.329 million riyals a year earlier, a drop of about 59%. Second-quarter premiums were only 3.862 million riyals, versus 263.552 million riyals a year earlier, down about 99%. Written premiums differ from insurance revenue, which reflects cover provided over time rather than the value of policies when written. Reading both series helps separate weakness in new policy production from revenue still earned on older contracts. Premiums will also be a useful measure in later disclosures of whether the flow of business recovers if the restriction changes.

The reported loss narrowed even as business contracted, making the earnings line alone an incomplete guide to operating strength. The insurer posted a net loss after zakat of 7.737 million riyals in the first half of 2026, compared with 104.861 million riyals in the same period of 2025. The company attributed most of the improvement to lower insurance-service expenses. Falling expenses can reduce a period's loss while premiums and revenue continue to weaken, so business volume must be read alongside the profit or loss. The smaller loss does not demonstrate that the insurer restored its ability to generate new policies, which the latest order now restricts across every product. For shareholders, the durability of any improvement depends on revenue, claims and expenses together rather than the loss comparison in isolation.

The balance sheet and auditor's comments identify risks distinct from the period's narrower loss. At 30 June 2026, shareholders' equity stood at 16.842 million riyals, down from 165.961 million riyals a year earlier, while accumulated losses reached 459.574 million riyals, or 115% of capital. The auditor cited 14.39 million riyals of first-half operating cash outflows and noncompliance with the required solvency ratio. It also identified material uncertainty that could cast significant doubt on the insurer's ability to continue operating. Those disclosures matter when assessing its capacity to withstand weaker business, but they do not quantify the additional cost of the all-product ban. The authority did not identify any one of those measures as the specific cause of its order, so their timing should not be turned into an asserted causal finding.

Court proceedings further complicate the position of shareholders and creditors. On 10 September 2026, the company disclosed a creditor's petition to the commercial court to open liquidation proceedings; its board also resolved that day to seek financial reorganization. A petition or board resolution does not itself mean the court has opened either process or determined the insurer's fate. The Capital Market Authority suspended trading in the shares from 13 September 2026 pending its decision following the court's ruling on the liquidation application. Accordingly, the insurance order cannot yet be described as producing visible selling pressure in a share that is not trading normally. The inability to sell during a suspension is distinct from the price the market might establish if trading later resumes.

The next developments run along separate regulatory and legal tracks. On the regulatory side, disclosures from the authority or the insurer about correcting violations and any restored permission to issue or renew policies would directly indicate whether new business can return. On the legal and market side, decisions from the court and the Capital Market Authority will determine the status of the suspended share and whether trading can resume. Subsequent financial statements can then test the direction of written premiums, cash flow and solvency against the position before the full-product ban. Until those disclosures arrive, the incremental financial cost of the order is unquantified, and no traded share-price response can be inferred. This sequence distinguishes developments already confirmed from outcomes dependent on later rulings or financial reports.